Salalori et al. reported a subject with T1DM with the translocation-ets-leukemia/platelet-derived growth factor receptor β (TEL/PDGFRβ) rearrangement mutation and symptomatic hypoglycemia that had a reduction in the insulin dosage after treatment with imatinib [22]. This evidence concerns the gene INS and type 1 diabetes mellitus.